samedan logo
 
 
 
spacer
home > pmps > winter 2001 > child-resistant clinical trials packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Child-Resistant Clinical Trials Packaging

Many pharmaceutical companies operating on a global basis are worried by the Consumer Product and Safety Commission's (CPSC) enforcement (which began on 23rd November 2000) of child-resistant packaging for clinical trials packs containing a potentially hazardous amount of drug, as part of America's Poison Prevention Packaging Act (PPPA). This could have a knock-on effect for the packaging of clinical trials in Europe with the recent introduction of the EU GCP Clinical Trials Directive, signed in December 2000 and to be implemented into member states legislation within two years.

Consumer groups in Europe are campaigning for standards for child resistance compliance to be brought more in line with the US protocol.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Colin Scaife, Managing Partner of C.E. Packaging Partnership
Colin Scaife formed C.E. Packaging Partnership to provide small and medium-sized pharmaceutical and health care companies with independent access to packaging development expertise and help in their understanding of legislation. He has over 30 years' experience of the packaging of pharmaceutical, health care and FMCGH products and is keen to promote innovative and practical packaging. He is Chairman of the joint ABPI/PAGB technical working party, monitoring packaging issues on behalf of the industry. He is also a recognised expert in the field of child-resistant packaging, being the Convenor of both the European and international standards committees, through which he drafts standards for the testing of child-resistant packaging.

spacer
Colin Scaife
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement